Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients
BACKGROUND: Limited studies have compared the impact of different antiretroviral regimens on soluble markers of inflammation with discordant results.
METHODS: In this prospective study, treatment naïve HIV-1-infected patients were included if they started their current regimen with atazanavir/ritonavir (ATV/r) (N = 73, Group 1) or darunavir/ritonavir (DRV/r) (N = 85, Group 2) plus tenofovir/emtricitabine. The analysis of IL-6, MCP-1, sCD163, VCAM-1, ox-LDL, and adiponectine was performed on two stored plasma samples, the first prior to antiretroviral therapy initiation and the second one year after initiation.
RESULTS: The results of our analysis show a difference in ox-LDL between the two groups with higher mean (SD) values in ATV/r based group 608.5 ± 137.4 versus 519.1 ± 119.6 in DRV/r group, after controlling for baseline levels of ox-LDL as well as other potential confounding factors controlled by means of matching design or linear regression modelling.
CONCLUSIONS: Our analysis provides further data examining the association between the modulation of vascular inflammatory and of activation markers with specific protease inhibitors-based treatments over one year of exposure to these drugs. The data show little evidence for an association, supporting the notion that antiretroviral regimens has generally poor efficiency in downregulating these soluble markers.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2018 |
|---|---|
| Erschienen: |
2018 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
HIV clinical trials - 19(2018), 4 vom: 01. Aug., Seite 158-162 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Dentone, Chiara [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.06.2019 Date Revised 13.06.2019 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1080/15284336.2018.1488453 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM290546362 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM290546362 | ||
| 003 | DE-627 | ||
| 005 | 20231225064955.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/15284336.2018.1488453 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0968.xml |
| 035 | |a (DE-627)NLM290546362 | ||
| 035 | |a (NLM)30422095 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Dentone, Chiara |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Inflammatory effects of atazanavir/ritonavir versus darunavir/ritonavir in treatment naïve, HIV-1-infected patients |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.06.2019 | ||
| 500 | |a Date Revised 13.06.2019 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: Limited studies have compared the impact of different antiretroviral regimens on soluble markers of inflammation with discordant results | ||
| 520 | |a METHODS: In this prospective study, treatment naïve HIV-1-infected patients were included if they started their current regimen with atazanavir/ritonavir (ATV/r) (N = 73, Group 1) or darunavir/ritonavir (DRV/r) (N = 85, Group 2) plus tenofovir/emtricitabine. The analysis of IL-6, MCP-1, sCD163, VCAM-1, ox-LDL, and adiponectine was performed on two stored plasma samples, the first prior to antiretroviral therapy initiation and the second one year after initiation | ||
| 520 | |a RESULTS: The results of our analysis show a difference in ox-LDL between the two groups with higher mean (SD) values in ATV/r based group 608.5 ± 137.4 versus 519.1 ± 119.6 in DRV/r group, after controlling for baseline levels of ox-LDL as well as other potential confounding factors controlled by means of matching design or linear regression modelling | ||
| 520 | |a CONCLUSIONS: Our analysis provides further data examining the association between the modulation of vascular inflammatory and of activation markers with specific protease inhibitors-based treatments over one year of exposure to these drugs. The data show little evidence for an association, supporting the notion that antiretroviral regimens has generally poor efficiency in downregulating these soluble markers | ||
| 650 | 4 | |a Comparative Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Vascular inflammation | |
| 650 | 4 | |a activation markers | |
| 650 | 4 | |a atazanavir | |
| 650 | 4 | |a darunavir | |
| 650 | 4 | |a first-line antiretroviral therapy | |
| 650 | 7 | |a Anti-HIV Agents |2 NLM | |
| 650 | 7 | |a Biomarkers |2 NLM | |
| 650 | 7 | |a Atazanavir Sulfate |2 NLM | |
| 650 | 7 | |a 4MT4VIE29P |2 NLM | |
| 650 | 7 | |a Ritonavir |2 NLM | |
| 650 | 7 | |a O3J8G9O825 |2 NLM | |
| 650 | 7 | |a Darunavir |2 NLM | |
| 650 | 7 | |a YO603Y8113 |2 NLM | |
| 700 | 1 | |a Di Biagio, Antonio |e verfasserin |4 aut | |
| 700 | 1 | |a Cozzi Lepri, Alessandro |e verfasserin |4 aut | |
| 700 | 1 | |a Fenoglio, Daniela |e verfasserin |4 aut | |
| 700 | 1 | |a Filaci, Gilberto |e verfasserin |4 aut | |
| 700 | 1 | |a Lichtner, Miriam |e verfasserin |4 aut | |
| 700 | 1 | |a Carrara, Stefania |e verfasserin |4 aut | |
| 700 | 1 | |a Giacometti, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a Sighinolfi, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Marchetti, Giulia |e verfasserin |4 aut | |
| 700 | 1 | |a Antinori, Andrea |e verfasserin |4 aut | |
| 700 | 1 | |a D'arminio Monforte, Antonella |e verfasserin |4 aut | |
| 700 | 0 | |a ICONA Foundation Study Group |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t HIV clinical trials |d 2000 |g 19(2018), 4 vom: 01. Aug., Seite 158-162 |w (DE-627)NLM114850178 |x 1528-4336 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2018 |g number:4 |g day:01 |g month:08 |g pages:158-162 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/15284336.2018.1488453 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 19 |j 2018 |e 4 |b 01 |c 08 |h 158-162 | ||